The patent further extends Lipid Sciences’s ownership over therapeutic HDL compositions provided by the company’s proprietary extracorporeal delipidation process. The company plans to capitalize on this strong IP position and recent encouraging clinical trial data by aggressively pursuing ongoing partnership discussions supporting commercialization of this promising medical technology.
Lipid Sciences’s selective delipidation technology removes lipids from a patient’s own HDL and then the delipidated HDL particles are returned to the patient. The delipidation process ‘energizes’ these HDL particles enabling them to pick up excess lipids from plaque in the arterial walls and transport those lipids to the liver where they are processed and excreted naturally from the body. This important biological process is known as reverse cholesterol transport.
Lewis Meyer, president and CEO of Lipid Sciences, said: “HDL therapy clearly represents the new frontier in the treatment of cardiovascular disease. HDL selective delipidation has the potential to be a safe, cost-effective solution to this significant clinical challenge.”